Urolithin A treatment led to increased p53 protein expression in 22RV1 and PC3 cells which subsequently resulted in the inhibition of MDM2-mediated p53 polyubiquitination [131], indicating that the presence of urolithin A possesses anti-cancer properties via its influence on the p53-MDM2 pathway. The gene discussed is MDM2; the disease is cancer.